-Company To Present at the 9th Annual ImVacS, The Immunotherapies and Vaccine Summit
August 13th, 2014
Liquidia Technologies today announced that it will present new data demonstrating the influence of tunable PRINT® (Particle Replication In Non-Wetting Templates) particle characteristics on the immune response as a component of vaccine development. Results from this preclinical study will be presented at the 9th Annual ImVacS, The Immunotherapies and Vaccine Summit, being held August 11-14, 2014 in Boston, Massachusetts. The ImVacS Summit brings together a global audience of vaccine researchers and developers of cancer immunotherapies for five focused meetings that explore the frontiers of immunology as the basis for patient treatment.
Michele Stone, Ph.D., PMP, Liquidia’s Director, Vaccines will give an oral presentation titled Exploring the Role of Size and Shape Impact on Immune Response through PRINT Technology in a special session, Vaccine Delivery Innovations, being held today at 3:45PM in Salon ABCG at the Marriott Long Wharf Hotel.
The PRINT technology is an innovative, highly tunable and scalable particle engineering process that allows Liquidia researchers to precisely tailor particle size, shape, charge, hydrophobicity, and composition of vaccines with the goal of optimizing a vaccine’s ability to elicit the desired immune response. By using a broad range of matrix materials formulated with active antigens and adjuvants, Liquidia has leveraged the PRINT technology to define particles of specific sizes and shapes that appear to have superior effects on humoral and cellular immune responses.
Vaccines are a front line defense against many, often life threatening diseases. Liquidia’s PRINT technology is aimed at finding innovative solutions that can address many of the challenges often encountered in vaccine development with the ultimate goal of creating safe and efficacious vaccines that can provide the broadest possible protection for a global population.